新常态 新未来——总结反思、为未来科学防控COVID-19行稳致远

胡善联

复旦学报(医学版) ›› 2020, Vol. 47 ›› Issue (04) : 467-471.

PDF(2548 KB)
欢迎访问《复旦学报(医学版)》官方网站,今天是 2025年5月2日 星期五 分享到:
PDF(2548 KB)
复旦学报(医学版) ›› 2020, Vol. 47 ›› Issue (04) : 467-471. DOI: 10.3969/j.issn.1672-8467.2020.04.001
专家论坛

新常态 新未来——总结反思、为未来科学防控COVID-19行稳致远

  • 胡善联
作者信息 +

New normal and new future: summing up and reflection for the future scientific prevention and control COVID-19 to ensure its enduring and steady progress

  • HU Shan-lian
Author information +
文章历史 +

摘要

目的 总结不同阶段我国防治COVID-19暴发流行的经验,反思存在的研究问题,探讨今后在疫情新常态情况下如何进一步做好科学精准的防制工作。方法 利用世界卫生组织和我国报告的疫情资料、文献和网络报道综合评述。结果 分析全球COVID-19疾病流行概况,总结我国三个流行阶段的经验。通过反思,对国内在COVID-19治疗药物研究、核酸和抗体检测以及疫情报告病例的标准出现的问题提出了一些建议。结论 今后COVID-19境外输入引起的散发或集聚发病将会成为一种新常态。在疫苗主动免疫实施以前,做好个人防护,加强社区群防群控,阻止输入病例形成社区传播,将成为未来的新局面。

Abstract

Objective To summarize the experience of prevention and control of COVID-19 epidemic in different stages in China,to reflect on the existing research problems and to explore how to do scientific and accurate prevention and control measurements in the new normal situation of COVID-19 infection. Methods The statistical data,literature and website reports from WHO and China were reviewed. Results The pandemic situation of COVID-19 in the world was analyzed,and the experience of three epidemic stages in China was summarized.Some suggestions on the clinical drug researches,nucleic acid and antibody detection and case notification of COVID-19 in China were put forward. Conclusion In the future,COVID-19 events will become a new normal due to the spread or clusters of cases caused by imported patients.Before the implementation of active immunization,it will be a new future situation to do personal protection,strengthen prevention and controlling the transmission of imported cases in the community.

引用本文

导出引用
胡善联. 新常态 新未来——总结反思、为未来科学防控COVID-19行稳致远[J]. 复旦学报(医学版), 2020, 47(04): 467-471 https://doi.org/10.3969/j.issn.1672-8467.2020.04.001
HU Shan-lian. New normal and new future: summing up and reflection for the future scientific prevention and control COVID-19 to ensure its enduring and steady progress[J]. Fudan University Journal of Medical Sciences, 2020, 47(04): 467-471 https://doi.org/10.3969/j.issn.1672-8467.2020.04.001
中图分类号: R183    F205   

参考文献

[1] WHO.WHO Coronavirus Disease (COVID) Dashboard[EB/OL].(2020-07-20)[2020-07-21].https://covid19.who.int/.
[2] WHO.Coronavirus disease (COVID-19) Situation Report-186[EB/OL].(2020-07-20)[2020-07-21].https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200724-covid-19-sitrep-186.pdf?sfvrsn=4da7b585-2.
[3] WANG YM,ZHANG DY,DU GH,et al.Remdesivir in adults with severe COVID-19:a randomised,double-blind, placebo-controlled,multicentre trial[J].Lancet,2020,395(10263):1569-1578.
[4] WIERSINGA WJ,RHODES A,CHENG AC,et al. Pathophysiology,transmission,diagnosis and treatment of coronavirus disease 2019(COVID-19)[J/OL].JAMA. (2020-07-10)[2020-07-21].http://pubmed.ncbi.nim.nih.gov/32648899/.
[5] 中国质量新闻网. 国家药监局已批准新冠病毒核算检测试剂10个,抗体检测试剂6个[N/OL].(2020-03-12)[2020-07-21].https://baijiahao.baidu.com/s?id=1660957328053009402.
[6] 荆楚网.北京,又增8例!新发地8186人核酸结果公布[N/OL].(2020-06-1)[2020-07-21].https://baijiahao.baidu.com/s?id=1669481933977106854.
PDF(2548 KB)

237

Accesses

0

Citation

Detail

段落导航
相关文章

/